A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Carvedilol Tablets USP 12.5 mg With Coreg 12.5 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carvedilol (Primary)
- Indications Angina pectoris; Heart failure; Hypertension
- Focus Pharmacokinetics
- 09 Jul 2012 Biomarkers information updated
- 18 Apr 2012 New trial record